Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
4.33
Nov 13 • 3:59 PM ET Dollar change-0.06 Percentage change(-1.37%)
Aftermarket Close
4.33
Aftermarket • 7:30 PM ET Dollar change0.00 Percentage change(0.00%)
Nov 13, 3:08 AMJourney Medical posts positive EBITDA again as Emrosi scripts, coverage and ASP improve
Index
-
Market Cap
122.21M
Enterprise Value
125.51M
Income
-5.10M
Sales
69.52M
Book/sh
1.14
Cash/sh
0.79
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
58
IPO
Nov 12, 2021
P/E
-
Forward P/E
13.75
PEG
-
P/S
1.76
P/B
3.79
P/C
5.48
P/FCF
-
EV/EBITDA
56.79
EV/Sales
1.81
Quick Ratio
1.34
Current Ratio
1.48
Debt/Eq
0.79
LT Debt/Eq
0.56
Option/Short
Yes / Yes
EPS (ttm)
-0.19
EPS next Y
0.32
EPS next Q
-0.03
EPS this Y
67.55%
EPS next Y
306.56%
EPS next 5Y
-
EPS past 3/5Y
34.88% -
Sales past 3/5Y
-5.66% 6.79%
EPS Y/Y TTM
49.40%
Sales Y/Y TTM
17.03%
EPS Q/Q
49.57%
Sales Q/Q
7.58%
Insider Own
48.50%
Insider Trans
0.00%
Inst Own
38.13%
Inst Trans
-5.89%
ROA
-5.40%
ROE
-17.56%
ROIC
-10.14%
Gross Margin
59.99%
Oper. Margin
-2.89%
Profit Margin
-7.34%
SMA20
-9.75%
SMA50
-26.50%
SMA200
-32.74%
Trades
Shs Outstand
22.23M
Shs Float
14.53M
52W High
9.56 -54.68%
52W Low
4.25 1.88%
Volatility
6.48% 6.86%
ATR (14)
0.33
RSI (14)
33.31
Beta
1.16
Rel Volume
2.04
Avg Volume
190.02K
Volume
387,169
Perf Week
-3.13%
Perf Month
-15.51%
Perf Quarter
-32.97%
Perf Half Y
-31.60%
Perf YTD
-43.84%
Perf Year
-43.69%
Perf 3Y
9.07%
Perf 5Y
-54.42%
Perf 10Y
-
Prev Close
4.39
Price
4.33
Change %
-1.37%
Consensus
Strong Buy
Avg. Price Target
$13.25
Implied Upside
+206.0%
Analysts4incl. previous ratings
Rating Distribution4 Buy · 0 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Aug 25, 2025Initiated
HH.C. Wainwright
Buy$13+200.2%
Jul 30, 2025Resumed
RILY logoRB. Riley Securities
Buy$12+177.1%
Aug 22, 2024Initiated
RRodman & Renshaw
Buy$9+107.9%
Jun 28, 2024Resumed
RROTH MKM
Buy$11+154.0%
Dec 07, 2021Initiated
RILY logoRB. Riley Securities
Buy$14+223.3%
Journey Medical Corporation is a commercial-stage pharmaceutical company, which focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. Its brands include QBREXZA, Accutane, Targadox, AMZEEQ, Ximino, ZILXI, Exelderm, and Luxamend. The company was founded by Claude Maraoui in October 2014 and is headquartered in Scottsdale, AZ.
Executive ChairmanDr. Lindsay Allan Rosenwald M.D.
FounderMr. Claude Maraoui
CFO & Corporate ControllerMr. Joseph M. Benesch
COOMr. Ramsey Alloush
Executive Director of MarketingMr. Brian Prout